BETH RESPESS: Open Payments
NPI 1710038682 · BRUNSWICK, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,290 in 47 payments from 13 companies in 2025. Trend: 2023 $939 · 2024 $814 · 2025 $1,290
Food & beverage: $1,287Education: $3
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 7 | $398 |
| Travere Therapeutics, Inc. | 8 | $195 |
| Novartis Pharmaceuticals Corporation | 7 | $172 |
| Otsuka America Pharmaceutical, Inc. | 6 | $126 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $79 |
| Xeris Pharmaceuticals, Inc. | 3 | $73 |
| Amgen Inc. | 3 | $70 |
| Calliditas Therapeutics US Inc. | 3 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
Products named: XPHOZAH 30 MG, IBSRELA, Filspari, JYNARQUE, Fabhalta, Kerendia, KEVEYIS, TAVNEOS.
Industry payments across GA — which companies pay providers there.
